RSLV 132

Drug Profile

RSLV 132

Alternative Names: RSLV-132

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Washington University
  • Developer Resolve Therapeutics
  • Class Anti-inflammatories; Biological proteins; Recombinant fusion proteins
  • Mechanism of Action B cell inhibitors; Interferon alpha inhibitors; Ribonuclease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 10 Feb 2016 Efficacy, adverse events and pharmacokinetics data from a phasee I trial in Systemic lupus erythematosus released by Resolve Therapeutics
  • 01 Jan 2016 Phase-II clinical trials in Systemic lupus erythematosus in USA (IV) (NCT02660944)
  • 30 Oct 2015 Resolve Therapeutics plans a phase IIa trial for Sjogren's syndrome (IV) (Resolve Corporate Review, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top